INTRODUCTION: Anesthetic preconditioning protects cardiomyocytes from oxidative stress-induced injury, but it is ineffective in patients with diabetes mellitus. To address the role of hyperglycemia in the inability of diabetic individuals to be preconditioned, we used human cardiomyocytes differentiated from induced pluripotent stem cells generated from patients with or without type 2 diabetes mellitus (DM-iPSC- and N-iPSC-CMs, respectively) to investigate the efficacy of preconditioning in varying glucose conditions (5, 11, and 25 mM). METHODS: Induced pluripotent stem cells were induced to generate cardiomyocytes by directed differentiation. For subsequent studies, cardiomyocytes were identified by genetic labeling with enhanced green fluorescent protein driven by a cardiac-specific promoter. Cell viability was analyzed by lactate dehydrogenase assay. Confocal microscopy was utilized to measure opening of the mitochondrial permeability transition pore and the mitochondrial adenosine 5'-triphosphate-sensitive potassium channels. RESULTS: Isoflurane (0.5 mM) preconditioning protected N-iPSC- and DM-iPSC-CMs from oxidative stress-induced lactate dehydrogenase release and mitochondrial permeability transition pore opening in 5 mM and 11 mM glucose. Isoflurane triggered mitochondrial adenosine-5'-triphosphate-sensitive potassium channel opening in N-iPSC-CMs in 5 mM and 11 mM glucose and in DM-iPSC-CMs in 5 mM glucose; 25 mM glucose disrupted anesthetic preconditioning-mediated protection in DM-iPSC- and N-iPSC-CMs. CONCLUSIONS: The opening of mitochondrial adenosine 5'-triphosphate-sensitive potassium channels are disrupted in DM-iPSC-CMs in 11 mM and 25 mM glucose and in N-iPSC-CMs in 25 mM glucose. Cardiomyocytes derived from healthy donors and patients with a specific disease, such as diabetes in this study, open possibilities in studying genotype- and phenotype-related pathologies in a human-relevant model.
INTRODUCTION: Anesthetic preconditioning protects cardiomyocytes from oxidative stress-induced injury, but it is ineffective in patients with diabetes mellitus. To address the role of hyperglycemia in the inability of diabetic individuals to be preconditioned, we used human cardiomyocytes differentiated from induced pluripotent stem cells generated from patients with or without type 2 diabetes mellitus (DM-iPSC- and N-iPSC-CMs, respectively) to investigate the efficacy of preconditioning in varying glucose conditions (5, 11, and 25 mM). METHODS: Induced pluripotent stem cells were induced to generate cardiomyocytes by directed differentiation. For subsequent studies, cardiomyocytes were identified by genetic labeling with enhanced green fluorescent protein driven by a cardiac-specific promoter. Cell viability was analyzed by lactate dehydrogenase assay. Confocal microscopy was utilized to measure opening of the mitochondrial permeability transition pore and the mitochondrial adenosine 5'-triphosphate-sensitive potassium channels. RESULTS:Isoflurane (0.5 mM) preconditioning protected N-iPSC- and DM-iPSC-CMs from oxidative stress-induced lactate dehydrogenase release and mitochondrial permeability transition pore opening in 5 mM and 11 mM glucose. Isoflurane triggered mitochondrial adenosine-5'-triphosphate-sensitive potassium channel opening in N-iPSC-CMs in 5 mM and 11 mM glucose and in DM-iPSC-CMs in 5 mM glucose; 25 mM glucose disrupted anesthetic preconditioning-mediated protection in DM-iPSC- and N-iPSC-CMs. CONCLUSIONS: The opening of mitochondrial adenosine 5'-triphosphate-sensitive potassium channels are disrupted in DM-iPSC-CMs in 11 mM and 25 mM glucose and in N-iPSC-CMs in 25 mM glucose. Cardiomyocytes derived from healthy donors and patients with a specific disease, such as diabetes in this study, open possibilities in studying genotype- and phenotype-related pathologies in a human-relevant model.
Authors: Katsuya Tanaka; Franz Kehl; Weidong Gu; John G Krolikowski; Paul S Pagel; David C Warltier; Judy R Kersten Journal: Am J Physiol Heart Circ Physiol Date: 2002-06 Impact factor: 4.733
Authors: Magdalena Juhaszova; Dmitry B Zorov; Suhn-Hee Kim; Salvatore Pepe; Qin Fu; Kenneth W Fishbein; Bruce D Ziman; Su Wang; Kirsti Ytrehus; Christopher L Antos; Eric N Olson; Steven J Sollott Journal: J Clin Invest Date: 2004-06 Impact factor: 14.808
Authors: Enis Novalija; Srinivasan G Varadarajan; Amadou K S Camara; Jianzhong An; Qun Chen; Matthias L Riess; Neil Hogg; David F Stowe Journal: Am J Physiol Heart Circ Physiol Date: 2002-07 Impact factor: 4.733
Authors: Chika Kikuchi; Martin Bienengraeber; Scott Canfield; Andrew Koopmeiner; Richard Schäfer; Zeljko J Bosnjak; Xiaowen Bai Journal: Cell Transplant Date: 2015-01-05 Impact factor: 4.064
Authors: Robert A Kloner; David A Brown; Marie Csete; Wangde Dai; James M Downey; Roberta A Gottlieb; Sharon L Hale; Jianru Shi Journal: Nat Rev Cardiol Date: 2017-07-27 Impact factor: 32.419
Authors: Shigang Qiao; Jessica M Olson; Mark Paterson; Yasheng Yan; Ivan Zaja; Yanan Liu; Matthias L Riess; Judy R Kersten; Mingyu Liang; David C Warltier; Zeljko J Bosnjak; Zhi-Dong Ge Journal: Anesthesiology Date: 2015-10 Impact factor: 7.892
Authors: Filip Sedlic; Maria Y Muravyeva; Ana Sepac; Marija Sedlic; Anna Marie Williams; Meiying Yang; Xiaowen Bai; Zeljko J Bosnjak Journal: J Cell Physiol Date: 2016-06-21 Impact factor: 6.384
Authors: Muhammad Z Afzal; Melanie Reiter; Courtney Gastonguay; Jered V McGivern; Xuan Guan; Zhi-Dong Ge; David L Mack; Martin K Childers; Allison D Ebert; Jennifer L Strande Journal: J Cardiovasc Pharmacol Ther Date: 2016-03-02 Impact factor: 2.457